![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATION AND IMMUNOPHARMACOLOGY
Department of Experimental Pharmacology, Faculty of Pharmacy, University of Naples-Federico II, Naples, Italy (F.R., M.B., V.B., G.C.); "George P. Livanos-Marianthi Simou" Laboratories, Department of Critical Care and Pulmonary Services, Evangelismos Hospital, University of Athens, Athens, Greece (S.T., A.K., A.P.); and Laboratory for Molecular Pharmacology, School of Pharmacy, University of Patras, Patras, Greece (A.P.)
Angiopoietins (Angs) are endothelium-selective ligands that exert most of their actions through the Tie-2 receptor. It is widely accepted that Ang-1 promotes the structural integrity of blood vessels and exhibits anti-inflammatory properties. In contrast, the role of Ang-2 remains less clear because it has been shown to behave as a Tie-2 agonist or antagonist under different experimental conditions. To define the role of Ang-2 in acute inflammation, we studied the effects of recombinant Ang-2 administration in vivo. We show herein that Ang-2, but not Ang-1, induces edema formation in the mouse paw in a dose-dependent manner; the edema seems to be fast-peaking (maximum at 30 min) and resolves within 4 h. The effect of Ang-2 is blocked by the coadministration with a soluble form of the Tie-2 receptor or Ang-1. NO and prostaglandin E2 levels in mouse paw following the injection of Ang-2 remained unaltered, suggesting that the action of Ang-2 does not involve these mediators. In addition, Ang-2 exerted a weak stimulatory effect on leukocyte migration in the mouse paw. Similarly, Ang-2 injected into the mouse air pouch produced only a modest effect on cell extravasation that peaked at 30 min. However, when cell migration was elicited using zymosan, Ang-2 significantly inhibited leukocyte migration. We conclude that Ang-2 by itself stimulates the extravasation of cell-poor fluid, but in the presence of ongoing inflammation it reduces cellular infiltration in tissues.
Address correspondence to: Dr. Andreas Papapetropoulos, Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece 26504. E-mail: apapapet{at}upatras.gr
This article has been cited by other articles:
|
|
 |
|
  A. H.J. Salmon, C. R. Neal, L. M. Sage, C. A. Glass, S. J. Harper, and D. O. Bates Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx Cardiovasc Res, July 1, 2009; 83(1): 24 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Melgar-Lesmes, S Tugues, J Ros, G Fernandez-Varo, M Morales-Ruiz, J Rodes, and W Jimenez Vascular endothelial growth factor and angiopoietin-2 play a major role in the pathogenesis of vascular leakage in cirrhotic rats Gut, February 1, 2009; 58(2): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Kuo, D. Patschan, S. Patschan, L. Cohen-Gould, H.-C. Park, J. Ni, F. Addabbo, and M. S. Goligorsky Ischemia-Induced Exocytosis of Weibel-Palade Bodies Mobilizes Stem Cells J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2321 - 2330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-X. Chen and A. Stinnett Ang-1 Gene Therapy Inhibits Hypoxia-Inducible Factor-1{alpha} (HIF-1{alpha})-Prolyl-4-Hydroxylase-2, Stabilizes HIF-1{alpha} Expression, and Normalizes Immature Vasculature in db/db Mice Diabetes, December 1, 2008; 57(12): 3335 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Tressel, H. Kim, C.-W. Ni, K. Chang, J. C. Velasquez-Castano, W. R. Taylor, Y.-s. Yoon, and H. Jo Angiopoietin-2 Stimulates Blood Flow Recovery After Femoral Artery Occlusion by Inducing Inflammation and Arteriogenesis Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 1989 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Li, W. Yin, X. Hong, Y. Shi, H.-S. Wang, S.-F. Lin, and S.-B. Tang Remodeling Retinal Neovascularization by ALK1 Gene Transfection In Vitro Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M van der Heijden, G P van Nieuw Amerongen, P Koolwijk, V W M van Hinsbergh, and A B J Groeneveld Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients Thorax, October 1, 2008; 63(10): 903 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Voskas, Y. Babichev, L. S. Ling, J. Alami, Y. Shaked, R. S. Kerbel, B. Ciruna, and D. J. Dumont An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice J. Leukoc. Biol., July 1, 2008; 84(1): 59 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. M. Simoes, T. Vassilakopoulos, D. Toumpanakis, K. Petrochilou, C. Roussos, and A. Papapetropoulos Angiopoietin-1 Protects against Airway Inflammation and Hyperreactivity in Asthma Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1314 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mofarrahi, T. Nouh, S. Qureshi, L. Guillot, D. Mayaki, and S. N. A. Hussain Regulation of angiopoietin expression by bacterial lipopolysaccharide Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L955 - L963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maliba, A. Brkovic, P.-E. Neagoe, L. R. Villeneuve, and M. G. Sirois Angiopoietin-mediated endothelial P-selectin translocation: cell signaling mechanisms J. Leukoc. Biol., February 1, 2008; 83(2): 352 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Liu, M. Han, and J.-K. Wen Acetylbritannilactone Inhibits Neointimal Hyperplasia after Balloon Injury of Rat Artery by Suppressing Nuclear Factor-{kappa}B Activation J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 292 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brkovic, M. Pelletier, D. Girard, and M. G. Sirois Angiopoietin chemotactic activities on neutrophils are regulated by PI-3K activation J. Leukoc. Biol., April 1, 2007; 81(4): 1093 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Ohab, S. Fleming, A. Blesch, and S. T. Carmichael A Neurovascular Niche for Neurogenesis after Stroke J. Neurosci., December 13, 2006; 26(50): 13007 - 13016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-G. Shyu Enhancement of new vessel formation by Angiopoietin-2/Tie2 signaling in endothelial progenitor cells: A new hope for future therapy? Cardiovasc Res, December 1, 2006; 72(3): 359 - 360. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Daly, E. Pasnikowski, E. Burova, V. Wong, T. H. Aldrich, J. Griffiths, E. Ioffe, T. J. Daly, J. P. Fandl, N. Papadopoulos, et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells PNAS, October 17, 2006; 103(42): 15491 - 15496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Nykanen, K. Pajusola, R. Krebs, M. A.I. Keranen, O. Raisky, P. K. Koskinen, K. Alitalo, and K. B. Lemstrom Common Protective and Diverse Smooth Muscle Cell Effects of AAV-Mediated Angiopoietin-1 and -2 Expression in Rat Cardiac Allograft Vasculopathy Circ. Res., June 9, 2006; 98(11): 1373 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kalomenidis, A. Kollintza, I. Sigala, A. Papapetropoulos, S. Papiris, R. W. Light, and C. Roussos Angiopoietin-2 Levels Are Elevated in Exudative Pleural Effusions Chest, May 1, 2006; 129(5): 1259 - 1266. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
